- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06370728
A Drug-Drug Interaction (DDI) Study of Orforglipron With Carbamazepine in Healthy Participants
April 26, 2024 updated by: Eli Lilly and Company
A Drug-Drug Interaction Study to Assess the Effect of Carbamazepine on the Pharmacokinetics of Orforglipron in Healthy Participants
The main purpose of this study is to assess the effect of carbamazepine on the amount of orforglipron in the bloodstream and how long it takes the body to get rid of orforglipron when given orally in healthy study participants.
The safety and tolerability of orforglipron and carbamazepine when given separately or together will also be evaluated.
The study may last up to approximately 77 days for each participant.
Study Overview
Status
Not yet recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
30
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: This is a single site clinical trial. 1-877-CTLILLY (1-877-285-4559) or
- Phone Number: 1-317-615-4559
- Email: ClinicalTrials.gov@Lilly.com
Study Locations
-
-
Texas
-
San Antonio, Texas, United States, 78209
- ICON Early Phase Services
-
Contact:
- Phone Number: 210-255-5437
-
Principal Investigator:
- Robert Bass
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Yes
Description
Inclusion Criteria:
- Participants must be overtly healthy individuals, assigned male at birth (AMAB) or individuals not of childbearing potential (INOCBP).
- Have a body weight equal to or greater than 45 kg, and body mass index (BMI) between 18.5 and 35.0 kilograms per meter squared (kg/m²), inclusive, at screening.
Have a hemoglobin level of
- at least 11.4 g/dL for individuals assigned female at birth (AFAB) and
- at least 12.5 g/dL for AMAB.
- Have venous access sufficient to allow for blood sampling.
Exclusion Criteria:
- Have a significant history of or current cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematological, psychological, or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs; of constituting a risk when taking orforglipron; or of interfering with the interpretation of data.
- Have an abnormal 12-lead electrocardiogram (ECG).
- Have human leucocyte antigen-B (HLA-B)*1502 or HLA-A*3101 allele; participants with other alleles that demonstrate strong evidence of association with carbamazepine-induced hypersensitivity reaction or hepatic impairment may also be excluded.
- Have a history or presence of multiple or severe allergies, or severe post treatment hypersensitivity reactions.
- Have known allergies to carbamazepine or to orforglipron, related compounds, or any components of the formulation.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Orforglipron + Carbamazepine
Single dose of orforglipron along with twice-daily dose of carbamazepine administered orally
|
Administered orally
Other Names:
Administered orally
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve from Time Zero to Infinity (AUC [0-∞]) of Orforglipron
Time Frame: Predose up to Day 18
|
PK: AUC (0-∞) of Orforglipron
|
Predose up to Day 18
|
PK: Area Under the Concentration Versus Time Curve from Time Zero to the Last Measurable Concentration (AUC[0-tlast]) of Orforglipron
Time Frame: Predose up to Day 18
|
PK: AUC (0-tlast) of Orforglipron
|
Predose up to Day 18
|
PK: Maximum Observed Concentration (Cmax) of Orforglipron
Time Frame: Predose up to Day 18
|
PK: Cmax of Orforglipron
|
Predose up to Day 18
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST), Eli Lilly and Company
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Estimated)
May 3, 2024
Primary Completion (Estimated)
July 15, 2024
Study Completion (Estimated)
July 15, 2024
Study Registration Dates
First Submitted
April 15, 2024
First Submitted That Met QC Criteria
April 15, 2024
First Posted (Actual)
April 17, 2024
Study Record Updates
Last Update Posted (Actual)
April 29, 2024
Last Update Submitted That Met QC Criteria
April 26, 2024
Last Verified
April 1, 2024
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Central Nervous System Depressants
- Peripheral Nervous System Agents
- Analgesics
- Sensory System Agents
- Analgesics, Non-Narcotic
- Tranquilizing Agents
- Psychotropic Drugs
- Membrane Transport Modulators
- Anticonvulsants
- Sodium Channel Blockers
- Antimanic Agents
- Cytochrome P-450 Enzyme Inducers
- Cytochrome P-450 CYP3A Inducers
- Carbamazepine
Other Study ID Numbers
- 18621
- J2A-MC-GZPJ (Other Identifier: Eli Lilly and Company)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy
-
Prevent Age Resort "Pervaya Liniya"RecruitingHealthy Aging | Healthy Diet | Healthy LifestyleRussian Federation
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
Yale UniversityNot yet recruitingHealth-related Benefits of Introducing Table Olives Into the Diet of Young Adults: Olives For HealthHealthy Diet | Healthy Lifestyle | Healthy Nutrition | CholesterolUnited States
-
Hasselt UniversityRecruitingHealthy | Healthy AgingBelgium
-
Galera Therapeutics, Inc.Syneos HealthCompleted
-
Galera Therapeutics, Inc.Syneos HealthCompletedHealthy | Healthy VolunteersAustralia
-
University of PennsylvaniaActive, not recruitingHealthy | Healthy AgingUnited States
-
Chalmers University of TechnologyGöteborg UniversityCompletedHealthy | Nutrition, HealthySweden
-
University of ManitobaNot yet recruitingHealthy | Healthy Diet
Clinical Trials on Orforglipron
-
Eli Lilly and CompanyRecruitingType 2 DiabetesUnited States, Mexico, Japan, India, Puerto Rico, China
-
Eli Lilly and CompanyActive, not recruiting
-
Eli Lilly and CompanyActive, not recruitingObesity | Overweight | Type 2 DiabetesUnited States, China, Australia, India, Germany, Greece, Argentina, Korea, Republic of, Brazil, Czechia, Puerto Rico
-
Eli Lilly and CompanyActive, not recruitingObesity | Overweight | Overweight or ObesityUnited States, China, India, Taiwan, Japan, Brazil, Puerto Rico, Spain, Slovakia, Korea, Republic of
-
Eli Lilly and CompanyRecruiting
-
Eli Lilly and CompanyRecruitingType 2 DiabetesUnited States, Japan, China, Puerto Rico, Romania, Brazil
-
Eli Lilly and CompanyRecruitingCardiovascular Diseases | Obesity | Overweight | Type 2 Diabetes | Chronic Kidney Disease | Overweight or ObesityUnited States, Italy, Spain, Korea, Republic of, India, Turkey, Austria, Puerto Rico, Mexico, Romania, Brazil, Germany, Argentina, Czechia, Greece, Slovakia
-
Eli Lilly and CompanyRecruitingType 2 DiabetesUnited States, China, Japan, Argentina, Puerto Rico, Mexico
-
Eli Lilly and CompanyRecruitingType 2 DiabetesUnited States, Taiwan, China, Mexico, Germany, Poland
-
Eli Lilly and CompanyRecruitingHealthy | Overweight | ObeseUnited States